Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.51 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456692 | 0.89 | HIF1A (0.67) | CACNA2D1HIF1AL3MBTL1VDAC2SLC7A11 | |
| SCHEMBL4461465 | 0.86 | CACNA2D1 (0.59) | CACNA2D1HIF1AVDAC2SLC7A11MEN1 | |
| SCHEMBL14447196 | 0.83 | GAA (0.53) | CACNA2D1L3MBTL1VDAC2SLC7A11TP53 | |
| SCHEMBL14304988 | 0.83 | VDAC2 (0.56) | CACNA2D1HIF1AL3MBTL1VDAC2SLC7A11 | |
| SCHEMBL13633681 | 0.80 | MEN1 (0.47) | L3MBTL1VDAC2SLC7A11TP53LMNA | |
| SCHEMBL13633616 | 0.80 | SLC7A11 (0.77) | HIF1AL3MBTL1VDAC2SLC7A11LMNA | |
| SCHEMBL14447195 | 0.79 | KMT2A (0.61) | VDAC2SLC7A11TP53MEN1KMT2A | |
| SCHEMBL1553118 | 0.79 | L3MBTL1 (0.61) | L3MBTL1TP53LMNAMEN1KMT2A | |
| SCHEMBL12610306 | 0.78 | VDAC2 (0.61) | CACNA2D1HIF1AVDAC2SLC7A11MEN1 | |
| SCHEMBL13633686 | 0.78 | VDAC2 (0.49) | HIF1AL3MBTL1VDAC2SLC7A11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | BAD, CASP3, BAX | CACNA2D1 4679/4885HIF1A 910/4885L3MBTL1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.